The expression of CD62L on neutrophils from severely psoriatic patients was lower than those from moderately psoriatic individuals and normal healthy controls, whereas neutrophils from psoriasis patients who received biologic treatments (infliximab or ustekinumab) had normal CD62L levels. This evidence concerns the gene SELL and psoriasis.